Brief: Palatin Technologies signs licensing agreement with Kwangdong Pharma
21/11/2017 12:30
Nov 21 (Reuters) - Palatin Technologies PTN.A
* Palatin Technologies announces signing of licensing
agreement
with Kwangdong Pharmaceutical for Republic of Korea
* A NDA anticipated to be filed with U.S. Food and Drug
Administration in Q1 of calendar year 2018
Source text for Eikon: ID:nPn4Rm8GVa
Further company coverage: AMAG.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Kwangdong Pharmaceutical
See all newsBrief: Kwangdong Pharmaceutical Q2 Operating Profit 2.8 Billion Won, Down 38% From Year Earlier
Brief: Kwangdong Pharmaceutical To Divest 25 Billion Won Worth Of Own Shares
Brief: Kwangdong Pharmaceutical To Divest 22 Billion Won Worth Of Own Shares
Ocugen up after licensing deal for ophthalmic gene therapy in South Korea
Brief: Kwangdong Pharmaceutical Q1 Operating Profit 3.3 Billion Won, Down 80.6% From Year Earlier